This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
FOXO4-DRI (10 mg Vial)
FOXO4-DRI (also known as Proxofim) is a synthetic D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4–p53 protein interaction[1][2]. When this interaction is blocked, p53 translocates to the mitochondria in senescent cells, triggering their programmed death while sparing healthy cells[1].
Quick Reference
What is FOXO4-DRI?
Research overview based on the cited scientific literature.
• Goal: Selectively clear senescent cells via disruption of FOXO4–p53 binding[1][2].
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw[8].
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure[8].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1 month when using bacteriostatic water[8].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
• If long-term storage of reconstituted solution is needed, aliquot into single-use vials and freeze to minimize degradation[8].
How is FOXO4-DRI studied?
FOXO4-DRI is a synthetic peptide that selectively targets senescent cells by blocking the FOXO4–p53 protein interaction[1][2]. In normal cells, FOXO4 binds to p53 and sequesters it in the nucleus. In senescent cells, disrupting this interaction causes p53 to translocate to the mitochondria, triggering apoptotic cell death specifically in aged, dysfunctional cells while sparing healthy ones[1]. Animal studies have demonstrated that FOXO4-DRI can reduce senescent cell burden, improve tissue function, and mitigate age-related pathologies[3][4][5]. The peptide’s D-retro-inverso configuration enhances its stability and resistance to proteolytic degradation[2].
What does the research report about FOXO4-DRI?
Observations from preclinical literature.
• Promotes selective clearance of senescent cells in various tissues, including aged organs and pathological conditions[3][4][5].
• Animal studies show improvements in tissue regeneration, reduced inflammation, and enhanced organ function following senescent cell clearance[3][5].
• In aged mice, FOXO4-DRI treatment improved testosterone levels and markers of cellular health[3].
• No human clinical safety or efficacy data currently exist[6]; tolerability in humans remains uncharacterized.
• Injection-site reactions (mild redness, irritation) may occur with subcutaneous administration[10].
Research Limitations / Risk Notes
No human clinical safety or efficacy data currently exist[6]; tolerability in humans remains uncharacterized.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.